Vertex Pharmaceuticals Inc (VRTX) Stock Analysis
Verdict: HOLD
Pipeline diversification into non-opioid pain and renal therapies reinforces high-margin CF growth, but a 29.7x P/E caps near-term re-rating.
Investment score: 62/100
Analysis as of
Is Vertex Pharmaceuticals Inc stock worth reviewing? AI model thesis
Vertex offers exceptional financial health and cash flow visibility, but elevated valuation (29.6x P/E) and insider selling suggest limited near-term multiple expansion.
7-factor investment score
- Valuation: 52/100 (weight 20%)
- Financial Health: 88/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Vertex Pharmaceuticals Inc opportunities and risks
What speaks for VRTX
- Monopolistic Cystic Fibrosis Franchise
What speaks against VRTX
- Valuation Premium relative to Large-Cap Biotech Peers
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VRTX | 29.6x | 10.3x | 23.2x | 86.0% | 34.9% | 2.9% |
| ABBV | 74.0x | 7.2x | 24.9x | 71.5% | 9.8% | 4.2% |
| AMGN | 23.2x | 5.3x | 14.9x | 72.7% | 22.9% | 5.0% |
| GILD | n/a | 6.0x | 324.6x | 79.6% | -10.6% | 7.2% |
| Peer median | 23.2x | 6.0x | 24.9x | 72.7% | 9.8% | 5.0% |
Frequently asked questions about Vertex Pharmaceuticals Inc (VRTX)
Is VRTX stock a good investment?
The cached TradeMates AI model rates Vertex Pharmaceuticals Inc as HOLD with an investment score of 62/100. Vertex offers exceptional financial health and cash flow visibility, but elevated valuation (29.6x P/E) and insider selling suggest limited near-term multiple expansion. This is algorithmic model output, not personal investment advice.
Is VRTX stock a buy?
The TradeMates model verdict for VRTX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.